Adverse Events of Pirfenidone for the Treatment of Pulmonary Fibrosis: A Meta-Analysis of Randomized Controlled Trials
Authors:
Open Access
- 9 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e47024
Abstract
Pirfenidone (PFD) is a novel antifibrotic agent approved for patients with pulmonary fibrosis. However, there are concerns regarding toxicity of the drug. In this meta-analysis, we analyzed the adverse events (AEs) of PFD for the treatment of pulmonary fibrosis. We performed a systematic search of PubMed, Embase, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials for trials published between January 1999 and October 2011. Data extracted from literature were analyzed with Review manager 5.0.24. The results of six randomized controlled trials (1073 participants) revealed that the number of individuals who discontinued PFD therapy was significantly higher than patients receiving placebo. The PFD group had a significantly higher rate of gastrointestinal (nausea, dyspepsia, diarrhea, and anorexia), neurological (dizziness and fatigue), and dermatological (photosensitivity and rash) AEs compared to the placebo group. PFD used for the treatment of pulmonary fibrosis is not so safe or well-tolerated. Notably, gastrointestinal, neurological and dermatological adverse effects were more common in patients receiving PFD therapy, and therefore appropriate precaution is needed.Keywords
This publication has 20 references indexed in Scilit:
- BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Single‐ and Multiple‐Dose Pharmacokinetics of Pirfenidone, an Antifibrotic Agent, in Healthy Chinese VolunteersThe Journal of Clinical Pharmacology, 2007
- Incidence and Prevalence of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- High-Dose Acetylcysteine in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2005
- Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Effect of pirfenidone on the pulmonary fibrosis of Hermansky–Pudlak syndromeMolecular Genetics and Metabolism, 2002
- Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone: Results of a Prospective, Open-label Phase II StudyAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Pirfenidone Attenuates Bleomycin-Induced Changes in Pulmonary Functions in HamstersExperimental Biology and Medicine, 1997
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters.1995